Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Leclanche Aktie 11030311 / CH0110303119

25.02.2026 07:00:10

Leclanché Appoints Jens Emrich as Chief Financial Officer

Leclanché SA / Key word(s): Personnel
Leclanché Appoints Jens Emrich as Chief Financial Officer

25-Feb-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR


Leclanché Appoints Jens Emrich as Chief Financial Officer

YVERDON-LES-BAINS, Switzerland, 25th of February, 2026 – Leclanché SA (SIX: LECN) announces the appointment of Jens Emrich as Chief Financial Officer, effective 1st March 2026.

Jens Emrich brings more than 25 years of international finance leadership experience across industrial and energy-related sectors. Most recently, he served as Director Financial Decision Support & Insight EMEA (Regional CFO) at Li-Cycle Europe AG, where he established and led the regional finance organisation for the NYSE-listed lithium-ion battery recycling company.

In this role, he oversaw financial governance, statutory reporting, cash management and capex deployment across multiple European jurisdictions and supported the scale-up of the company’s German operations.

Previously, he held senior finance leadership positions at Key Surgical Europe (part of Steris plc), LBNUTS AG and Lorenz Snack-World, where he led financial transformation, integration and restructuring initiatives.

Pierre Blanc, CEO of Leclanché Group, commented: “Jens brings strong experience in financial transformation, industrial scale-up and international governance. His expertise will be instrumental as we continue to strengthen our financial structure and support the company’s next phase of development”.

Further information on Mr. Emrich’s background will be available on the Company’s website.

 

# # #

 

About Leclanché

Leclanché is a world leading provider of low-carbon footprint energy storage solutions based on lithium-ion cell technology. Established in 1909 in Yverdon-les-Bains, Switzerland, Leclanché’s history and heritage is rooted in battery and energy storage innovation. The company’s Swiss culture for precision and quality, together with its production facilities in Germany, make Leclanché the partner of choice for companies seeking the very best in battery performance and who are pioneering positive changes in how energy is produced, distributed and consumed around the world. Leclanché is organised into three business units: energy storage solutions, e-Mobility solutions and specialty battery systems. The company currently employs over 350 people with representative offices in eight countries around the world. Leclanché is listed on the Swiss Stock Exchange (SIX: LECN).

SIX Swiss Exchange : ticker symbol LECN | ISIN CH 011 030 311 9

 

Disclaimer

This press release contains certain forward-looking statements relating to Leclanché's business, which can be identified by terminology such as "strategic", "proposes", "to introduce", "will", "planned", "expected", "commitment", "expects", "set", "preparing", "plans", "estimates", "aims", "would", "potential", "awaiting", "estimated", "proposal", or similar expressions, or by expressed or implied discussions regarding the ramp up of Leclanché's production capacity, potential applications for existing products, or regarding potential future revenues from any such products, or potential future sales or earnings of Leclanché or any of its business units. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of Leclanché regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Leclanché's products will achieve any particular revenue levels. Nor can there be any guarantee that Leclanché, or any of the business units, will achieve any particular financial results.

 

Media contacts: 

Switzerland / Europe: 
Thierry Meyer
T: +41 (0) 79 785 35 81
E-Mail: tme@dynamicsgroup.ch

Germany:
Christoph Miller
T: +49 (0) 711 947 670
E-Mail: leclanche@sympra.de

Investor contacts:
Pierre Blanc
T: +41 (0) 24 424 65 00
E-Mail: invest.leclanche@leclanche.com



End of Inside Information
Language: English
Company: Leclanché SA
Av. des Sports 42
1400 Yverdon-les-Bains
Switzerland
Phone: +41 (24) 424 65-00
Fax: +41 (24) 424 65-20
E-mail: investors@leclanche.com
Internet: www.leclanche.com
ISIN: CH0110303119, CH0016271550
Valor: A1CUUB, 812950
Listed: SIX Swiss Exchange
EQS News ID: 2281064

 
End of Announcement EQS News Service

2281064  25-Feb-2026 CET/CEST

Analysen zu Leclanche (Leclanché SA)

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Im neuesten BX Morningcall ist Dr. Anna Erat zu Gast – Spezialistin für Innere Medizin, Sportmedizin, Prävention und Longevity. Gemeinsam mit Olivia Hähnel und François Bloch sprechen wir darüber, was Longevity wirklich bedeutet (Healthspan vs. Lifespan), warum es mehr ist als Biohacking und wie man seriöse Angebote von Hype unterscheidet.

Dr. Erat gibt Einblick, wie eine erste Longevity-Konsultation abläuft, welche Rolle Anamnese, Genetik/Epigenetik und Technologie/AI spielen und worauf Patientinnen und Patienten bei der Wahl eines Anbieters achten sollten. Ausserdem: Versicherung & Kostenübernahme in der Schweiz, Erwartungsdruck bei High-Performance-Klienten und ein spannender Case: Wie würde sie mit Lindsey Vonn nach einer Verletzung umgehen?

https://bxplus.ch/bx-musterportfolio/

Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 14’565.14 19.17 S21BUU
Short 14’836.06 14.00 SWOBGU
Short 15’441.81 8.67 SY7BHU
SMI-Kurs: 13’989.96 25.02.2026 17:09:33
Long 13’388.25 19.31 SVZBNU
Long 13’111.66 14.00 S52B1U
Long 12’537.85 8.92 SXEBEU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com